Vaccines have been one of the faster growing areas of the pharmaceutical industry, and during a troubling series of years, they have been the superstars of many companies' portfolios. They've also attracted the attention of insurance companies, retail outlets and the media. The global market for vaccines experienced strong growth through 2009 and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions.
Kalorama Information has been closely following vaccine markets and since 2006 has instituted a yearly market research report schedule to keep up with fast-moving developments. Our latest comprehensive update, Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, examines the market for vaccines used in humans for various disease. This state-of-the-industry report is a must-have for any executive who wants to stay on top of a rapidly changing market and see what’s expected down the road. You can count on the objectivity and accuracy of our numbers and analysis—whether you're preparing a strategic presentation, benchmarking your company's performance against the competition, preparing a new product launch or seeking out an acquisition or a new partnership.
The report covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable.
Included in this report are current market size and forecast for the following vaccines:
Important trends such as vaccine safety, vaccine shortages, preventing pandemics, vaccines and bioterrorism, DNA vaccination, innovations in vaccine delivery systems and innovations in vaccine Production are covered in the report. In addition, the reort profiles key competitors in the vaccine industry. Companies profiled in the report include:
Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the historic 2005 to 2009 period and forecasts are provided through 2014. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.
Global Vaccine Market Exceeds $20 Billion: Kalorama
Vaccines continue to be the success story for pharmaceutical companies, with the world market for preventative vaccines totaling $22.1 billion in 2009, up from $19 billion in 2008, according to healthcare market research publisher Kalorama Information. Kalorama’s new report, Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, notes that the worldwide vaccine market is predicted to increase at a compound annual rate of 9.7% during the next five years, as new product introductions continue and the use of current products expands further.
“We’ve forecasted a high growth rate for vaccines over the past few years and market events have matched our predictions,” said Bruce Carlson, publisher of Kalorama Information. “The vaccine business is not without its risks, but for some companies, vaccines were the only bright spot in their portfolio in 2009. It’s not a surprise therefore that development is heavy in this sector, and that will contribute to growth over the next five years.”
Vaccines are commonly segmented into two target markets, adult and pediatric. According to Kalorama Information, the pediatric vaccine market is larger, accounting for more than half of the total market. Pediatric vaccines are also growing at a faster rate than adult vaccines and this is expected to continue over the next five years. Pneumococcal and “combination” DTaP vaccines are driving growth in the pediatric sector, while influenza and hepatitis vaccine products are driving sales in the adult segment of the market. Future growth in adult vaccines will be driven by increased acceptance and new products.
The worldwide vaccine market is dominated by five major competitors: Merck & Co, GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Novartis. These companies have made earning a greater share of the vaccine market part of their marketing and research strategies. GlaxoSmithKline is in the lead with nearly a quarter of the world market in 2009, largely due to its influenza products Fluvarix and Hiberix, according to Kalorama.
More information is available from Kalorama Information’s report, Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, including market forecasts, company profiles, and trends in the industry.
Related Reports:Surgical Procedure Volumes: Global Analysis (US, China, Japan, Brazil, UK, Germany, Italy, France, Mexico)
Feb 22, 2014 - KLI5205473 - $2,995.00
The Worldwide Market for Respiratory Devices (Inhalers, Nebulizers, Airways, Masks, Sleep Apnea, Oxygen Therapy, Ventilators Medical Humidifiers, Respiratory Measurement)
Jan 23, 2014 - KLI5192151 - $3,995.00
The World Market for Molecular Diagnostics Six Month Update
Jan 14, 2014 - KLI5181507 - $2,995.00
The World Market for Infusion Pumps (Large Volume Pumps, Ambulatory Pumps, Insulin Pumps, Enteral Feeding Pumps, Others)
Jan 6, 2014 - KLI5177834 - $3,995.00
The World Market for Hematology
Nov 22, 2013 - KLI5156915 - $3,995.00
The World Market for Medical Beds
Nov 8, 2013 - KLI5153655 - $3,995.00
The World Market for Immunoassays
Nov 6, 2013 - KLI5146358 - $3,995.00
The World Market for Infectious Disease Diagnostic Tests
Oct 21, 2013 - KLI5137619 - $3,995.00
The Global Market for Biomarkers (Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers)
Oct 16, 2013 - KLI5136277 - $3,995.00
The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition
Sep 22, 2013 - KLI5123810 - $1,995.00
Questions?Contact a research specialist >
Most Popular ResearchWhy Epigenomics May Be a Game-Changer in Diagnostics and Pharmaceuticals World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas) Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline) Vaccines 2012-16 World Market Analysis, Key Players, Trends, Pediatric and Adult Segments The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives